A Profile On European Healthtech
A Profile On European Healthtech
Words Founders Factory
March 30th 2026 / 7 min read
For years, the story told about European healthtech followed a familiar arc of world-class science, exceptional clinical rigour and a talent base that could hold its own against any ecosystem globally. And then somewhere between the lab and the market a structural gap swallowed companies whole.
That story is no longer accurate and evidence from the most credible institutions tracking this space suggests it may not have been the full picture for some time.
Interested in receiving more insights like this? Join our 38,000 Startup Bulletin newsletter subscribers
Subscribe on SubstackSubscribe on LinkedInWhy A System Under Pressure Creates Opportunity
To understand why AI health technology is attracting serious capital and institutional attention in Europe, it helps to understand the scale of the problem it is being asked to solve.
EU health systems have long-faced the mounting pressures of ageing populations and rising chronic disease rates, driving up demand just as labour shortages constrain healthcare delivery. According to the OECD, 20 EU countries reported a shortage of doctors in 2022 and 2023, while 15 countries reported a shortage of nurses. Based on minimum staffing thresholds for universal health coverage, EU countries had an estimated shortage of approximately 1.2 million doctors, nurses and midwives in 2022. Over one-third of doctors and a quarter of nurses in the EU are aged over 55 and expected to retire in the coming years.
The demographic pressures compounding this are long-term and structural. The proportion of people over 65 in the EU is projected to rise from 21% in 2023 to 29% by 2050. Life expectancy at age 65 now exceeds 20 years, but more than half of these years are impaired by chronic illnesses and disabilities.
Ageing populations and workforces demonstrate that this is not a crisis that can be solved by hiring alone. The scale of what is required demands a fundamental rethinking of how care is delivered, coordinated and optimised and that is precisely where AI-enabled health technology enters the picture.
The Capital Shift
Investment is following the urgency. VC backing for EU startups combining AI with healthcare, drugs and biotechnology has accelerated sharply, increasing from negligible levels before 2018 to $331 million in 2020 and doubling to nearly $670 million in 2024. Healthcare represented 7% of total VC investments in AI startups in the European Union in 2024 – a figure that, while still below its potential relative to the scale of the challenge, reflects a meaningful shift in investor conviction.
As we progress through 2026, healthcare organisations are embracing artificial intelligence technology to an unprecedented degree across a wide range of activities, from patient care to clinical workflows to drug discovery and development. Boston Consulting Group projects that the market for AI in healthcare will expand rapidly from this base, with health systems increasingly moving from being consumers of medtech solutions to becoming technology creators, developing proprietary algorithms from clinical data.
The breadth of what European founders are building across this landscape is striking. At the access and diagnostics layer, Scan.com, founded by UK radiologist Khalid Latief, has built the UK's largest marketplace for self-pay MRI, CT, ultrasound and X-ray scans, enabling patients to book imaging appointments in minutes without a GP referral, and has since expanded into the US market after a £43m Series B.
At the frontier of drug discovery, London-based Peptone is applying computational physics and AI to intrinsically disordered proteins, a class of targets implicated in Alzheimer's, cancer and diabetes that have historically been undruggable because their lack of fixed structure makes them impossible to model through conventional means, having raised $42 million from Bessemer Venture Partners, F-Prime Capital and Novartis.
And in the clinical capability layer, Fundamental XR is building VR haptic simulation infrastructure that allows surgeons to train on complex procedures at scale, backed by EQT Life Sciences with total funding exceeding $30 million. Three companies. Three layers of the same system. Each addressing a structural gap that the European ecosystem is uniquely positioned to solve.
The Structural Advantage European Founders Carry
There is something worth examining carefully in the European healthtech profile that does not always receive the attention it deserves. The clinical evidence base that European founders build, operate within, and often in direct partnership with, public health systems is genuinely different in character from what founders in most other markets typically produce.
The NHS, despite its pressures, provides access to patient populations and longitudinal data that most health systems cannot match. Academic medical centres across Germany, the Netherlands, Sweden, and the UK are embedded in research infrastructure that produces clinicians who think like scientists. The regulatory rigour of UKCA and CE marking pathways, while demanding, produces companies with a depth of clinical validation that sophisticated buyers increasingly recognise and value.
Policy is now beginning to extend this structural advantage significantly. The European Health Data Space, which came into force in 2025, empowers individuals to take control of their health data and facilitates the exchange of data for the delivery of healthcare across the EU — and according to the European Commission, will help advance cutting-edge AI solutions while ensuring compliance with data protection and ethical standards. The 1+ Million Genomes Initiative also enables secure access to genomic and corresponding clinical data across Europe, with 26 member states building the Genomic Data Infrastructure. By harnessing genomic data and enabling cross-border research, the initiative should help identify similar patient cases and accelerate the resolution of rare and undiagnosed diseases, supported increasingly by AI.
The European Commission believes Artificial intelligence in healthcare can give Europe a triple win of better healthcare outcomes for citizens, improved financial sustainability of healthcare systems and a more competitive economy.This backing by Europe’s interstate institutions captures precisely why the support for this category is substantive rather than rhetorical. The framework for cross-country collaboration in healthtech and AI has already been laid.
The Gap That Remains
None of this changes a structural reality that European founders building in health tech face when they look beyond their home markets. The United States remains the world's largest and most commercially significant healthcare market by a considerable margin. And for European companies it remains one of the hardest to enter.
The challenge is not one of product quality or clinical credibility. The challenge is relational and structural. The US healthcare system is built on institutional relationships between technology vendors and health system procurement committees, founders and the clinical champions who shepherd adoption, between early-stage companies and the investors who understand the specific dynamics of the American payer environment.
The fragmentation of European regulatory and reimbursement environments is also a genuine constraint on building scale domestically before attempting a US entry. Despite the promise and availability of AI-based tools in the market, their deployment in clinical practice is slow with challenges spanning technological and data-related issues, legal and regulatory complexities, organisational and business challenges, and social and cultural barriers.
The Market Is Rewarding Those Who Move Before It Does
The companies attracting the strongest attention and partnerships are those that can demonstrate durable clinical adoption, evidence that satisfies demanding procurement committees, and a credible path to commercial scalability. The next era of care will be led by healthcare institutions that own their AI agenda, not by those that wait for the ecosystem to shape it for them.
This creates a specific opportunity for European founders. The clinical rigour that European healthtech ecosystems demand, sometimes to the frustration of founders who want to move faster – turns out to be exactly what sophisticated health system buyers in the US are increasingly looking for. The challenge is creating the conditions for that evidence to be seen, validated, and acted upon within the US system. The World Health Organsation believes AI is transforming health systems, reshaping how care is planned, delivered and governed and that the founders who will define this category are those who find structured, credible pathways into the markets where commercial returns match the ambition of what they are building.
The Window Is Open
The conditions that have historically constrained European health tech founders are shifting in ways that are structural, not cyclical. The data infrastructure is maturing. The regulatory environment, while complex, is beginning to provide the clarity that serious investment requires. The clinical talent is there. The evidence base is being built, and increasingly, it is being recognised by the global capital and institutional partners who matter most.
What has changed most visibly in the past two years is the appetite from investors, health systems, and policymakers to close the gap between European innovation and real-world deployment at scale. The question is no longer whether European health tech can compete globally, the evidence suggests it already does. The question is whether the founders, funders and institutions operating in this space move with the urgency that the scale of the problem demands.
Ageing populations, overstretched workforces and rising chronic disease burdens are not problems that will wait for the ecosystem to fully mature. The health systems that will define the next decade of care are the ones being built right now (by founders who understand that clinical rigour and commercial ambition are not in tension, but are in fact the same thing). And the investors and institutions that will shape this category are those who recognise that Europe's structural advantage in this space is real, time-limited, and worth backing decisively.
The window is open, but it won’t stay that way indefinitely.
Founders Factory has launched a new cross-border healthcare accelerator with Chicago-based Northwestern Medicine, one of America’s leading healthcare systems.
The partnership will bring Europe’s top AI and deeptech health startups into the world’s largest healthcare market.
Latest articles
trends
A Profile On European Healthtech
What has changed most visibly in the past two years is the appetite from investors, health systems, and policymakers to close the gap between European innovation and real-world deployment at scale.
founder stories
Myonerv founder Sam Kamali: Why We Deliberately Jumped Into the Deep End of Stroke Rehabilitation
There's a huge population of people with chronic, severe paralysis who are desperate for something that actually works for them, and nobody is really building for them. That's where we wanted to go.
founder stories
RemoteSolar's Michael Schmitz: European Energy Sovereignty Starts at the Household Level
What would it mean for ordinary people to have a meaningful stake in their own energy supply?